Skip to main content
Quest Diagnostics

Clinical and Economic Outcomes of a Pharmacogenomics-Enriched Comprehensive Medication Management Program in a Self-Insured Employee Population

Clinical and Economic Outcomes of a Pharmacogenomics-Enriched Comprehensive Medication Management Program in a Self-Insured Employee Population

Authors: Fragala MS, Keogh M, Goldberg SE, Lorenz RA, Shaman JA

Citation: Pharmacogenomics J. 2024 Oct 2;24(5):30. doi: 10.1038/s41397-024-00350-1.

Specialties: Genetics, Neurology, Prescription Drug Monitoring, Toxicology, Population Health

 

 

 

 

 

Related content

On-Demand Webinar
Current state of Pharmacogenomics and its future
Publication
Role of Pharmacogenomics in Comprehensive Medication Management: Considerations for Employers
Publication
Early insights from a pharmacogenomic-enriched comprehensive medication management program implementation in an adult employee population
Audio Podcast
Pharmacogenomics in Mental Health and Addiction

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.